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The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in
a number of emerging targeted therapies. In just the last year, several new studies have been able to translate our
understanding of tumor biology into significantly improved outcomes in patients with advanced RCC. The objective
of this review is to describe new developments in targeted treatments and immunotherapies for patients with both
clear-cell and non-clear cell metastatic RCC following the 2014 American Society of Clinical Oncology (ASCO) annual
conference. We will discuss new applications of anti-VGF agents and PD-1 inhibitors in order to shed light on emerging
avenues of RCC treatment that show considerable promise.
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With the development of multiple anti-VEGF (vascular
endothelial growth factor) agents and mTOR (mammalian
target of rapamycin) inhibitors, we have seen significant
progress over the last few years in targeted therapies for
treating renal cell carcinoma (RCC). While these targeted
therapies were largely tested in patients with the more
common clear cell RCC (ccRCC), recent studies have
begun to investigate the efficacy of targeted therapy in the
much less common, non-clear cell RCC (nccRCC). In
addition, a number of new studies have, for the first time,
examined the activity of new immunotherapies in treating
ccRCC. In this article, we performed a brief review of re-
cent studies on the treatment of RCC with an update from
2014 annual ASCO meeting.
Review
RCCs are characterized by a vast array of different histo-
logical and cytogenetic signatures. Of approximately
64,000 cancers of the kidney every year [1], 80% are clear
cell renal cell carcinoma (ccRCC) and 20% are non–clear
cell renal cell carcinoma (nccRCC) subtypes.
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unless otherwise stated.and cancer stem cell development. It is important to note
that the more common ccRCC has often been tied to the
occurrence of von Hippel-Lindau (VHL) mutations impli-
cated in VEGF signaling deregulation [2]. Such mutations
have been found to contribute to an accumulation of tran-
scription factor HIF1α (hypoxia-inducible factor 1-alpha)
and, consequently, increased levels of VEGF and other
growth factors. Because the up-regulation of VEGF activity
has corresponded to the uncontrolled modulation of the
hypoxic response, multiple agents (e.g., sorafenib, suniti-
nib, bevacizumab, pazopanib, axitinib, temsirolimus,
everolimus) have been identified as abrogators of VEGF-
mediated signaling [3,4]. These therapeutic agents operate
through a variety of mechanisms, many of which abrogate
specific components of the VEGF signaling (TKIs for
VEGFR, bevacizumab for VEGF).
In addition to VEGF pathway deregulation, mTOR
kinase is a well-known contributor to tumorigenesis.
Given that a number of downstream mTOR effectors
regulating angiogenesis, metabolism, and cell growth
have been found to be deregulated in cancers, various
targeted therapies such as temsirolimus and everolimus
have been developed to hinder mTOR signaling. These
two mTOR signaling-based therapies will be discussed
in upcoming paragraphs.This is an Open Access article distributed under the terms of the Creative
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In recent years, a considerable number of tyrosine-
kinase inhibitors (TKIs) have been developed that seek
to target VEGF signaling in ccRCC. Among the most
prevalent of such targeted ccRCC therapies are TKIs
such as pazopanib, sorafenib, and axitinib, which have
been found to lead to significantly improved outcomes
for metastatic renal cell carcinoma (mRCC) patients. For
instance, bevacizumab, a humanized anti-VEGF anti-
body, was found in phase III randomized controlled tri-
als (RCTs) to contribute to significant increases in
progression-free survival in mRCC patients who had
used interferon alfa as first-line treatment [5]. An oral
angiogenesis inhibitor (pazopanib) targeting VEGFR,
PDGFR (platelet-derived growth factor receptor), and
the c-kit tyrosine kinase were found to demonstrate sig-
nificant improvements in progression-free survival and
tumor response in both treatment-naive and pre-treated
patients with mRCC [6]. Paralleling pazopanib’s effects,
sorafenib (an oral multikinase inhibitor of VEGF recep-
tors, platelet-derived growth factor receptors, and Raf ki-
nases) was found in a phase III RCT to contribute to
significantly longer median progression-free survival in
mRCC patients compared to placebo [7]. Building off
the trial’s promising results, a more recent phase III
RCT revealed that the second-generation inhibitor of
VEGF receptors, axitinib, culminated in even longer
progression-free survival (PFS) than sorafenib, support-
ing this VEGFR inhibitor’s suitability as a second-line
therapies for mRCC [8]. Besides VEGF inhibition,
mTOR inhibitors such as temsirolimus (an inhibitor of
rapamycin kinase) have also been found to significantly
improve overall survival (OS) among mRCC patients
with poor prognosis [9].
While the efficacy of TKIs in treating metastatic
ccRCC has been well established, a new body of research
has sought to examine the therapeutic value of TKIs in
treating mRCC patients with bone metastases (BM),
long considered one of the most destructive of mRCC
complications. Despite the high prevalence of BM, ther-
apies for BM management have been very limited in ad-
vanced renal cell carcinoma in light of the poorer
prognosis that patients with BM have relative to those
who do not have BM. In a retrospective review of 375
mRCC patients presented in this year’s ASCO annual
meeting, the median survival of BM patients using TKI
was found to be significantly longer than those who had
not used TKIs [22 months (95% CI: 17–25) vs. 14 months
(95% CI: 10–19), p < 0.01] [10]. However, mRCC pa-
tients with BM who were treated with TKIs were ob-
served to have a similar median OS as patients without BM
(p = 0.66). It necessitates emphasis that this study was lim-
ited by its retrospective nature, lack of randomization or
blinding, and accuracy of documentation. Future prospectiveclinical trials may be warranted to better understand the
interplay between different TKIs and their efficacy on mRCC
patients with BM.
New immunotherapy (PD-1 inhibitors) for clear cell RCC
Besides targeted therapies, immunotherapies seeking to
break tumor tolerance are another area of interest in the
RCC research community. Instead of directly targeting
malignant cells and stroma, immunotherapies work to
up-regulate the host immune response in order to des-
troy neoplastic cells that escape immune recognition.
An immune signaling mechanism of particular interest
to cancer clinicians is the PD-1 pathway. A potent im-
mune checkpoint receptor, programmed death-1 (PD-1)
is a cell-surface glycoprotein on T cells, B cells, and
macrophages that inhibits their activation. In recent
years, therapeutic agents inhibiting the PD-1 pathway
and increasing the strength of the host’s anti-tumor im-
mune response have been found to show therapeutic ef-
ficacy in the treatment of various cancers. This past year,
for instance, the PD-1 agent pembrolizumab (MK-3475)
was found to contribute to a 1-year survival rate of 69%
in metastatic melanoma patients with prior systematic
therapies of ipilimumab, leading to its FDA approval for
use in second-line settings [11]. In a separate PD-1 in-
hibitor trial, the monoclonal antibody nivolumab (used
in combination with ipilimumab) was found to produce
a 1-year 85% survival rate and 2-year 79% survival rate
in advanced melanoma patients [12]. In another phase 1
study, this time on patients with metastatic renal cell
carcinoma, nivolumab and ipilimumab were found to
contribute to a response rate of 43% (N3 + I1 arm; nivo-
lumab at 3 mg/kg and ipilimumab at 1 mg/kg) and 48%.
(N1 + I3 arm; nivolumab at 1 mg/kg and ipilimumab at
3 mg/kg). The aforementioned study’s results were en-
couraging, for the N3 + I1 arm was found to have a me-
dian progression-free survival of 36.6 weeks, whereas the
N1 + I3 arm had a median progression free survival of
38.3 weeks [13].
Mirroring their efficacy in treating melanoma, PD-1
inhibitors have also been found to be potent agents in
the treatment of RCC. Given that the PD-L1 ligand has
been found to be correlated with poor mRCC prognosis,
a number of PD-1 inhibitors (nivolumab, lambrolizu-
mab, ZBMS-936559, MPDL3280A, AMP-224) are cur-
rently being investigated for their therapeutic efficacy
[14]. In addition to its demonstrated therapeutic activity
in treating melanoma, nivolumab has been found to
have significant benefits in the treatment of mRCC. In a
phase II study of nivolumab’s activity in clear-cell mRCC
patients pretreated with anti-VEGR agents presented in
ASCO 2014 annual meeting, researchers examined dose–
response relationships, overall survival, objective response
rate, and drug safety [15]. Patients were randomized and
Xu and Wu Biomarker Research  (2015) 3:5 Page 3 of 5blinded to receive nivolumab at three different doses: at
0.3 mg/kg, 2 mg/kg, or 10 mg/kg. Although no dose–re-
sponse relationship for progression-free survival (PFS) was
found, significant anti-tumor activity was observed with
the usage of nivolumab, including objective responses of
relatively long duration. While the 0.3 mg/kg group had
an overall survival (OS) of 18.2 months, median OS were
not reached for other groups. Across doses, 19 out of 35
responders (54%) had objective responses lasting greater
than 12-20+ months. Overall, nivolumab was considered
to be well-tolerated, for less than 17% of patients (across
all doses) experienced grade 3–4 adverse events [15].
Despite its demonstrated activity, there is limited bio-
marker data to predict the therapeutic effect provided by
nivolumab in treating clear-cell mRCC. A recent study
presented in ASCO 2014 annual meeting, however, has
provided valuable insight on the molecular mechanisms
underlying nivolumab’s activity by examining the serum
of mRCC patients treated with nivolumab for chemo-
kines and T cell infiltrates at baseline, day 8 of cycle 2
(biopsy), and day 2 of cycle 1 (serum) [16]. Employing a
phase I open-label study design with four parallel treat-
ment arms (1–3 for patients with previously treated
mRCC, arm 4 for treatment-naïve nRCC patients), the
Choueiri et al. research team accumulated data on overall
response rate, safety/tolerability, and treatment-induced
changes in PD-L1 expression. Evidenced by increases in
interferon-gamma signaling, T-cell tumor infiltrates in bi-
opsies, and serum concentrations of CXCL9 and CXCL10,
nivolumab was found to have significant clinical activity in
91 patients with both mRCC previously treated with TKIs
and treatment-naive mRCC. The researchers observed an
increase in immune activity for both serum chemokines
CXCL9 (191%) and CXCL10 (90%), as well as an increase
in T cell infiltrates by 70% (CD3+) and 88% (CD8+).
Changes in biomarkers were consistent with PD-1 in-
hibition and provided evidence of immunomodulatory
effects in serum and in the tumor microenvironment.
The objective response rate was 16% (16% in previously
treated patients; 13% in untreated patients), and the me-
dian duration of response was 15 months. Responses
were numerically higher in PD-L1+ patients but were
also seen in PD-L1− patients. The promising results of
the Choueiri et al. trial will hopefully pave the way for
future biomarker-based studies that examine links be-
tween therapeutic doses and the molecular activity of
biological agents implicated in pharmacodynamics and
cancer cell function.
Targeted therapy for non-clear cell RCC
While the RCC therapies discussed above were for the
treatment of clear-cell renal cell carcinoma, the optimal
systemic therapy for non-clear cell renal cell carcinoma
remains a topic of debate among clinicians. While themost common histological classification among nccRCCs
is papillary renal cell carcinoma (10-15%), other histolo-
gies include chromophobes (5-10%), oncocytomas, renal
medullary carcinomas, collecting-duct carcinomas, sarco-
matoid, and unclassified nccRCCs. Given that VHL
mutations do not play a role in the non-clear cell renal
carcinoma disease course, it is unclear whether anti-
angiogenic TKIs targeting VEGF–a standard of care in the
treatment of clear-cell RCC–would have a therapeutic
benefit to mRCC patients. In addition, the relative rarity of
non-clear cell RCC in comparison to ccRCC poses a
challenge to clinical researchers seeking to gain insights
on a possible link between TKIs and non-clear cell RCC
pathogenesis.
Despite these challenges, researchers have begun examin-
ing the novel application of VEGFR TKIs in the treatment
of non-clear cell RCC and have found evidence suggestive
that VEGF TKIs have therapeutic value in the treatment of
nccRCC. Two drugs in particular, sunitinib and the mTOR
inhibitor everolimus, have been investigated for their pos-
sible treatment benefits in nccRCC patients. In 2007, suniti-
nib, the aforementioned orally administered inhibitor of
tyrosine kinases ranging from VEGFRs to PDGFRs, was
found to contribute to significantly higher progression-free
survival and response rate in mRCC patients participating
in a phase III trial [17]. In the following year, another phase
III trial led by the Motzer et al. group revealed that everoli-
mus prolonged progression-free survival compared to pla-
cebo in a sample of mRCC patients after sorafenib and/or
sunitinib treatment [18].
In a randomized phase 2 trial of non-clear cell RCC pre-
sented in the 2014 ASCO annual meeting (the ESPN trial),
researchers sought to evaluate the assumption that mTOR
inhibitors like everolimus may benefit “poor-risk” disease
patients such as those with nccRCC in terms of improved
progression-free survival and overall survival. Employing a
crossover study design, researchers evaluated the premise
that median PFS would be improved from 12 weeks with
sunitinib to 20 weeks with everolimus. Amid a sample of
68 participants (27 papillary, 11 chromophobe, 9 unclassi-
fied, 7 translocated, 13 sarcomatoid, 1 oncocytic), re-
searchers noted significantly higher overall survival in the
sunitinib arm (not reached vs 10.5 months, p = 0.01).
Chromophobe histology was also found to have better
overall survival and progression-free survival than other
histologies in both arms [19].
Because of the superior overall survival among partic-
ipants taking sunitinib, the ESPN study was prematurely
terminated as recommended by data and safety moni-
toring committee; differences in progression-free sur-
vival were consequently not observed in the first-line
between sunitinib (6.1 months) and everolimus
(4.1 months, p = 0.6). Following cross-over, the
progression-free survival in the second line was relatively
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mus (p = 0.6). Based on futility analysis for progression-
free survival and inferior overall survival with everolimus
compared to sunitinib in the first-line setting, termination
of further patient accrual was recommended for the trial,
and consequently everolimus was not recommended as a
first-line treatment option in nccRCC. It warrants em-
phasis that everolimus does not target mTOR complex 2,
which has been identified as a powerful driver of tumor
proliferation [20]. Given that the targeting of mTOR-2
could potentially contribute to RCC treatment benefits,
future research is needed on the efficacy of therapies that
target components of the mTOR signaling besides solely
mTOR-1.
Conclusions
In summary, the metastatic ccRCC treatment landscape–
previously dominated by targeted therapies–could be altered
significantly with the advent of potent immunotherapies
that abrogate the PD-1 pathway. However, targeted therap-
ies such as TKIs continue to hold much promise in the
management of clear cell and nccRCC. Future randomized-
controlled studies are needed in order to determine if new
PD-1 inhibitors or their combination withTKIs may provide
survival benefits in the treatment of RCC.
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